MA prior-auth response windows tighten in April. Your appeal rights got broader.

If your agency has a meaningful Medicare Advantage book, two CMS changes effective in April are worth your authorization team's attention. The headlines are about MA plans tightening, but the practical effect is that agencies have more recourse than they did 90 days ago.

What changed

• Response timeline: MA plans must respond to prior authorization requests within 72 hours for urgent requests and 7 days for standard requests. Late responses can be treated as constructive approvals (subject to plan rules).
• Organization determinations: Decisions made mid-course of care (e.g., reducing approved visits, denying continuation, changing service type) are now classified as "organization determinations" — meaning they're appealable through the Medicare appeals process, not just the plan's internal grievance.
• Stricter denial documentation: Plans denying coverage that Medicare FFS would have covered now have stricter documentation requirements.

Why this matters operationally

The federal audit that prompted these changes found roughly 13% of MA prior-auth denials should have been approved per Medicare coverage rules. Your agency's experience may have been worse than that — particularly if you had to fight for skilled nursing visit counts or PT durations the same patient would have gotten without question on FFS.

The new rules don't make MA easier to deal with day-to-day. They make recourse easier when the plan denies inappropriately. Agencies that had been writing off marginal authorization disputes as "not worth fighting" should reconsider — the appeal pathway now has more teeth.

What your authorization team needs to do

1. Retrain on the new appeal pathway for organization determinations. The 60-day appeal window starts from the date of the organization determination, not from when you noticed it.
2. Track response timelines. Late MA responses now have legal weight. Document when you submitted the prior-auth request and when the plan responded.
3. Keep clinical documentation tight on continuation requests. Plans denying coverage that would have been approved under FFS rules now need to justify the denial in writing — your clinical notes are the counterweight.
4. Set internal denial-appeal rates as a KPI. If you're not appealing 30%+ of MA denials, you're leaving money on the table that you now have a clearer path to.

What this won't fix

None of the rule changes affect the underlying MA economics. Plans still need to manage utilization to hit their MLR targets, and they're not going to suddenly become friendlier just because the appeal pathway tightened. Expect denial rates to stay where they are (or rise as plans get more selective in what they preauthorize). What changes is your ability to win the disputes.

What we built for this

Carelytic's authorization workflow tracks request submission timestamps, response timestamps, and decision rationale per authorization line. When an MA plan responds late, the platform flags it. When a continuation denial comes in, the appeal-window countdown starts automatically and surfaces in the authorization team's worklist. Pre-built appeal-letter templates pull in the underlying clinical documentation so the appeal package goes out within hours, not weeks.

The deeper opportunity: MA isn't going away — UnitedHealthcare and Humana now handle a meaningful share of the home health book in most markets. The agencies that build muscle memory around fast, well-documented appeals will see their MA realization rate rise materially in CY2026.